Political will is needed to address absence of sufficient financial incentives for new drugs

  20 November 2021

Half a century after he helped oversee the launch of amoxicillin, one of the world’s most widely used antibiotics, Bill Burns has come out of retirement to support an initiative to develop urgently needed replacements. While Covid-19 has put the spotlight on the threat posed by new viruses, Burns is just as worried about the underlying “silent pandemic” of antimicrobial resistance. As chair of the $1bn AMR Action Fund — which supports companies conducting later-stage trials of experimental drugs — he is next year set to approve the first in a series of grants to underwrite companies’ tests of experimental new antibiotics.

Further reading: Financial Times
Author(s): Andrew Jack
Effective Surveillance  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!